{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:26:48Z","timestamp":1782228408021,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Nobelpharma Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s13555-023-00914-2","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T06:02:45Z","timestamp":1678514565000},"page":"1113-1126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Topical Sirolimus 0.2% Gel for the Management of Tuberous Sclerosis Complex-Related Cutaneous Manifestations: An Interim Analysis of Postmarketing Surveillance in Japan"],"prefix":"10.1007","volume":"13","author":[{"given":"Akemi","family":"Egami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kokubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreedevi","family":"Boggarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Beresford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"issue":"4","key":"914_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Northrup H, Roberds S, et al. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):255\u201365.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"914_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaad.2007.05.004","volume":"57","author":"RA Schwartz","year":"2007","unstructured":"Schwartz RA, Fern\u00e1ndez G, Kotulska K, J\u00f3\u017awiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol. 2007;57(2):189\u2013202.","journal-title":"J Am Acad Dermatol"},{"key":"914_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","volume":"123","author":"H Northrup","year":"2021","unstructured":"Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021;123:50\u201366.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"914_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063910","volume":"8","author":"M Wataya-Kaneda","year":"2013","unstructured":"Wataya-Kaneda M, Tanaka M, Hamasaki T, Katayama I. Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients. PLoS\u00a0One. 2013;8(5):e63910.","journal-title":"PLoS\u00a0One"},{"issue":"3","key":"914_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1590\/abd1806-4841.20186972","volume":"93","author":"LKL Portocarrero","year":"2018","unstructured":"Portocarrero LKL, Quental KN, Samorano LP, Oliveira ZNP, Rivitti-Machado MCDM. Tuberous sclerosis complex: review based on new diagnostic criteria. An Bras Dermatol. 2018;93(3):323\u201331.","journal-title":"An Bras Dermatol"},{"issue":"4","key":"914_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s13555-020-00387-7","volume":"10","author":"M Wataya-Kaneda","year":"2020","unstructured":"Wataya-Kaneda M, Nagai H, Ohno Y, et al. Safety and efficacy of the sirolimus gel for TSC patients with facial skin lesions in a long-term, open-label, extension, uncontrolled clinical trial. Dermatol Ther (Heidelb). 2020;10(4):635\u201350.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"914_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jamadermatol.2018.1408","volume":"154","author":"M Wataya-Kaneda","year":"2018","unstructured":"Wataya-Kaneda M, Ohno Y, Fujita Y, et al. Sirolimus gel treatment vs placebo for facial angiofibromas in patients with tuberous sclerosis complex a randomized clinical trial. JAMA Dermatol. 2018;154(7):781\u20138.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"914_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","volume":"153","author":"M Wataya-Kaneda","year":"2017","unstructured":"Wataya-Kaneda M, Nakamura A, Tanaka M, et al. Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex a randomized clinical trial. JAMA Dermatol. 2017;153(1):39\u201348.","journal-title":"JAMA Dermatol"},{"issue":"1\u20132","key":"914_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000489089","volume":"234","author":"YI Lee","year":"2018","unstructured":"Lee YI, Lee JH, Kim DY, Chung KY, Shin JU. Comparative effects of topical 0.2% sirolimus for angiofibromas in adults and pediatric patients with tuberous sclerosis complex. Dermatology. 2018;234(1\u20132):13\u201322.","journal-title":"Dermatology"},{"issue":"3","key":"914_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","volume":"12","author":"MK Koenig","year":"2012","unstructured":"Koenig MK, Hebert AA, Roberson J, et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D. 2012;12(3):121\u20136.","journal-title":"Drugs R D"},{"key":"914_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2020.00001","volume":"7","author":"T Okanishi","year":"2020","unstructured":"Okanishi T, Fujimoto A, Enoki H, Ogai M. Early sirolimus gel treatment may diminish angiofibromas and prevent angiofibroma recurrence in children with tuberous sclerosis complex. Front Med. 2020;7:1\u20137.","journal-title":"Front Med"},{"issue":"7","key":"914_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamadermatol.2018.0464","volume":"154","author":"MK Koenig","year":"2018","unstructured":"Koenig MK, Bell CS, Hebert AA, et al. Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex the TREATMENT randomized clinical trial. JAMA Dermatol. 2018;154(7):773\u201380.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"914_CR13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jaad.2018.10.070","volume":"80","author":"S Leducq","year":"2019","unstructured":"Leducq S, Giraudeau B, Tavernier E, Maruani A. Topical use of mammalian target of rapamycin inhibitors in dermatology: a systematic review with meta-analysis. J Am Acad Dermatol. 2019;80(3):735\u201342.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"914_CR14","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1111\/bjd.12567","volume":"169","author":"M Tanaka","year":"2013","unstructured":"Tanaka M, Wataya-Kaneda M, Nakamura A, Matsumoto S, Katayama I. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex. Br J Dermatol. 2013;169(6):1314\u20138.","journal-title":"Br J Dermatol"},{"issue":"9869","key":"914_CR15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817\u201324.","journal-title":"Lancet"},{"issue":"9","key":"914_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023379","volume":"6","author":"SL Dabora","year":"2011","unstructured":"Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS\u00a0One. 2011;6(9): e23379.","journal-title":"PLoS\u00a0One"},{"issue":"9861","key":"914_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125\u201332.","journal-title":"Lancet"},{"issue":"10056","key":"914_CR18","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153\u201363.","journal-title":"Lancet"},{"issue":"17","key":"914_CR19","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595\u2013606.","journal-title":"N Engl J Med"},{"issue":"2","key":"914_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1399-0012.2010.01232.x","volume":"24","author":"JM Campistol","year":"2010","unstructured":"Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant. 2010;24(2):149\u201356.","journal-title":"Clin Transplant"},{"key":"914_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/403280","volume":"2013","author":"G Zaza","year":"2013","unstructured":"Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol. 2013;2013: 403280.","journal-title":"Clin Dev Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00914-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-00914-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00914-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T17:07:45Z","timestamp":1682874465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-00914-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["914"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-00914-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}